Christine M. O'Brien,1 Kevin Bishop,1 Xiao Xu,1 Leonid Shmuylovich,1 Elizabeth Conley,1 Suman B. Mondal,1 Karen Nwosu,1 Haini Zhang,1 Kathleen Duncan,1 Steve Vanko,1 Samuel Achilefuhttps://orcid.org/0000-0002-3133-67171
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Fluorescence guided surgery has high potential for improved patient outcomes but often lacks quantification of fluorophore depth which is needed to determine surgical margins of solid tumors. To address this need, a dual wavelength excitation approach was applied that capitalizes on the wavelength-dependent attenuation of light in tissue to provide depth information independent of fluorophore concentration. A portable near infrared dual wavelength excitation fluorescence imaging system was built and tested using tissue mimicking phantoms and is currently being tested to determine breast tumor margin status in a first-in-human clinical trial investigating LS301, a novel near infrared tumor-targeted contrast agent.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Christine M. O'Brien, Kevin Bishop, Xiao Xu, Leonid Shmuylovich, Elizabeth Conley, Suman B. Mondal, Karen Nwosu, Haini Zhang, Kathleen Duncan, Steve Vanko, Samuel Achilefu, "Quantitative tumor depth determination in fluorescence guided surgery," Proc. SPIE PC11949, Advanced Biomedical and Clinical Diagnostic and Surgical Guidance Systems XX, PC1194905 (9 March 2022); https://doi.org/10.1117/12.2614088